Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionAxa S.a.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Axa S.a. closes position in ALNY / Alnylam Pharmaceuticals, Inc.

On November 14, 2025 - Axa S.a. filed a 13F-HR form disclosing ownership of 0 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 82,480 shares of Alnylam Pharmaceuticals, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -100.00 0
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 82,480 -6,172 -6.96 26,896 12.36 0.0773
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 88,652 -6,654 -6.98 23,938 6.74 0.0786
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,306 -15,910 -14.31 22,426 -26.68 0.0681
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 111,216 241 0.22 30,588 13.43 0.0906
2025-02-25 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 110,975 3,339 3.10 26,967 67.64 0.0802
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 110,975 3,339 26,967 0.0802
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 107,636 -59,417 -35.57 16,086 -49.69 0.0482
2024-07-16 2023-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 167,053 -10,424 -5.87 31,976 1.73 0.1031
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 167,053 -10,424 31,976 0.0626
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 177,477 -1,322 -0.74 31,431 -7.45 0.1105
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 178,799 5,033 2.90 33,961 -2.43 0.1129
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 173,766 -27,650 -13.73 34,809 -27.28 0.1197
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 201,416 13,576 7.23 47,867 27.31 0.1727
2023-02-14 2022-09-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 187,840 -10,618 -5.35 37,598 29.89 0.1479
2022-11-14 2022-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 187,840 -10,618 37,598 0.1479
2023-02-14 2022-06-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 198,458 -9,438 -4.54 28,945 -14.73 0.1073
2022-08-15 2022-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 198,458 -9,438 28,946 0.1073
2023-02-14 2022-03-31 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 207,896 -5,808 -2.72 33,947 -6.33 0.0965
2022-05-13 2022-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 207,896 -5,808 33,948 0.0965
2022-02-14 2021-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 213,704 52,272 32.38 36,240 18.90 0.0926
2021-11-15 2021-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 161,432 42,426 35.65 30,480 51.09 0.0855
2021-08-13 2021-06-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 119,006 -39,466 -24.90 20,174 -9.84 0.0569
2021-08-13 2021-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 119,006 -39,466 20,174 0.0341
2021-05-14 2021-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 158,472 20,513 14.87 22,375 24.78 0.0681
2021-02-12 2020-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 137,959 8,741 6.76 17,931 -4.69 0.0563
2021-02-11 2020-09-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 129,218 4,257 3.41 18,814 1.65 0.0680
2020-11-13 2020-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 129,218 4,257 18,814 37,555.7300
2021-02-12 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 124,961 5,313 4.44 18,508 42.11 0.0729
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 124,961 5,313 18,508 72,988.9989
2021-02-12 2020-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 119,648 -16,167 -11.90 13,024 -16.73 0.0651
2020-06-15 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 119,648 0 13,024 0.0651
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 119,648 -16,167 13,024 36,219.9680
2021-02-12 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 135,815 -30,589 -18.38 15,641 16.88 0.0636
2020-02-18 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 135,815 -30,589 15,641 63,684.8042
2021-02-12 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 166,404 -363 -0.22 13,382 10.60 0.0533
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 166,404 -363 13,382 53,328.1219
2021-02-12 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 166,767 3,138 1.92 12,100 -20.87 0.0472
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 166,767 3,138 12,100 47,451.1107
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 163,629 -271 -0.17 15,291 27.96 0.0598
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 163,900 89,821 121.25 11,950 84.30 0.0521
2018-11-08 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 74,079 74,079 6,484 0.0238
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,884 -100.00 0 -100.00
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,884 1,884 225 0.0009
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -40,316 -100.00 0 -100.00
2017-12-01 2017-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 40,316 -100,894 -71.45 4,737 -57.94 0.0204
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,316 -100,894 4,737
2017-08-10 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 141,210 -103,073 -42.19 11,263 -10.04 0.0511
2017-05-11 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 244,283 116,121 90.60 12,520 160.94 0.0565
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 128,162 2,428 1.93 4,798 -43.70 0.0225
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 125,734 72 0.06 8,522 22.21 0.0374
2016-08-11 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 125,662 26,973 27.33 6,973 12.56 0.0311
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 98,689 33,116 50.50 6,195 0.36 0.0278
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 65,573 -1,378 -2.06 6,173 14.74 0.0270
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,951 -1,416 -2.07 5,380 -34.35 0.0221
2015-08-13 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 68,367 0 0.00 8,195 14.79 0.0328
2015-05-13 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 68,367 4,830 7.60 7,139 15.84 0.0294
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 63,537 4,065 6.84 6,163 32.68 0.0247
2014-11-13 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 59,472 33,403 128.13 4,645 182.03 0.0199
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,069 -1,048 -3.86 1,647 -9.56 0.0069
2014-05-13 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,117 27,117 1,821 0.0079
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.